Nitrooleic Acid, an Endogenous Product of Nitrative Stress, Activates Nociceptive Sensory Nerves via the Direct Activation of TRPA1

Thomas E. Taylor-Clark, Srinivas Ghatta, Weston Bettner, and Bradley J. Undem

Department of Medicine, Johns Hopkins University, Baltimore, Maryland (T.E.T.-C., W.B., B.J.U.); and Target Discovery, Respiratory and Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (S.G.)

Received December 23, 2008; accepted January 26, 2009

ABSTRACT

Transient Receptor Potential A1 (TRPA1) is a nonselective cation channel, preferentially expressed on a subset of nociceptive sensory neurons, that is activated by a variety of reactive irritants via the covalent modification of cysteine residues. Excessive nitric oxide during inflammation (nitrative stress), leads to the nitration of phospholipids, resulting in the formation of highly reactive cysteine modifying agents, such as nitrooleic acid (9-0A-NO2). Using calcium imaging and electrophysiology, we have shown that 9-0A-NO2 activates human TRPA1 channels (EC50, 1 μM), whereas oleic acid had no effect on TRPA1. 9-0A-NO2 failed to activate TRPA1 in which the cysteines at positions 619, 639, and 663 and the lysine at 708 had been mutated. TRPA1 activation by 9-0A-NO2 was not inhibited by the NO scavenger carboxy-PTIO. 9-0A-NO2 evoked robust action potential discharge from capsaicin-sensitive fibers with slow conduction velocities (0.4 – 0.7 m/s), which was inhibited by the TRPA1 antagonist AP-18. These data demonstrate that nitrooleic acid, a product of nitrative stress, can induce substantial nociceptive nerve activation through the selective and direct activation of TRPA1 channels.

Oxidative stress and nitrative stress have been implicated as contributing to acute and chronic inflammation (Radi, 2004; Szabó et al., 2007; Valko et al., 2007). Nitric oxide (NO) is an endogenous mediator with multiple cellular functions that is produced by many cell types including vascular endothelium, neutrophils, fibroblasts, and nerves (Bian and Murad, 2003). NO, generated from L-arginine by NO synthases (NOS), reacts with reactive oxygen species (ROS) to form reactive nitrogen species (RNS), peroxynitrite (ONOO−), and nitroglycerin dioxide (*NO2). RNS are potent inflammatory molecules that can react with lipids, proteins, and DNA (Szabó et al., 2007). Within membranes, where the hydrophobic environment maximizes RNS production (Möller et al., 2007), RNS react with unsaturated fatty acids (e.g., oleic acid), causing the addition of an NO2 group (nitration) (Freeman et al., 2008; Jain et al., 2008; Trostchansky and Rubbo, 2008). Nitrosated fatty acids (e.g., nitrooleic acid) are highly reactive electrophilic compounds that can modulate a variety of cellular targets, including thiol residues and peroxisome proliferator-activated receptor γ (Freeman et al., 2008; Trostchansky and Rubbo, 2008).

Received: December 23, 2008; accepted: January 26, 2009.

This work was supported by the National Institutes of Health National Heart, Lung, and Blood Institute (Grant K99-HL088520); GlaxoSmithKline; and the Blaustein Pain Research Fund.

Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org. doi: 10.1124/mol.108.054445.

ABBREVIATIONS: NOS, nitric oxide synthase; ROS, reactive oxygen species; RNS, reactive nitrogen species; OA, oleic acid; OA-NO2, nitrooleic acid; 4HNE, 4-hydroxynonenal; TRP, transient receptor potential; AITC, allyl isothiocyanate; HEK, human embryonic kidney; FBS, fetal bovine serum; AM, acetyloxymethyl ester; HC030031, 2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide; 4ONE, 4-oxononenal; PTIO, 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide; SIN-1, 3-morpholino-sydnonimine; AP-18, 4-(4-chlorophenyl)-3-methylbut-3-en-2-oxime; hTRPA1-HEK, HEK cells stably transfected with human TRPA1 channels; hTRPV1-HEK, HEK cells stably transfected with human TRPV1 channels.

http://molpharm.aspetjournals.org at ASPET Journals on June 20, 2017 molpharm.aspetjournals.org Downloaded from
Nitrated fatty acids are detectable in vitro after exposure of fatty acids to RNS donors (O’Donnell et al., 1999; Jain et al., 2008). Nitrated fatty acids have been measured in human plasma and red blood cells, with total nitrooleic acid (OA-NO2) and total nitrolinoleic acid concentrations in plasma of 920 and 630 nM, respectively (Baker et al., 2005). It is noteworthy that, unlike oxidative stress-produced reactive unsaturated aldehydes such as 4-hydroxynonenal (4HNE) that tend to break off from the phospholipid during peroxidation (Gardner, 1989), 32% of OA-NO2 in plasma and 72% in packed red blood cells is esterified (bound within phospholipid) (Baker et al., 2005). The intriguing possibility exists that esterified nitrated fatty acids represent a sink of bioactive mediators produced during nitrative stress that can induce subsequent cellular functions after liberation from the membrane by phospholipase A2 (Jain et al., 2008).

Inflammation elicits pain and reflexes as a result of the activation of somatosensory and visceral nociceptive sensory nerves. Recently, a member of the transient receptor potential (TRP) ion channel family termed TRPA1 has been demonstrated preferentially on nociceptive sensory nerves and is activated by irritants such as allyl isothiocyanate (AITC), cinnamaldehyde, bradykinin, and phytocannabinoids (Bandelier et al., 2004; Jordt et al., 2004; Bautista et al., 2006; De Petrocellis et al., 2008). ROS and reactive lipid peroxidation products have been shown to activate nociceptive neurons via TRPA1 (Bautista et al., 2006; Macpherson et al., 2007b; Trevisani et al., 2007; Andersson et al., 2008; Taylor-Clark et al., 2008a,b), probably via the direct covalent modification of key N-terminal cysteine groups (Hinman et al., 2006; Macpherson et al., 2007a; Trevisani et al., 2007). Given that the nitro group (NO2) is one of the strongest electron-drawing groups known, and given that the rate constants for cysteine addition by nitrated fatty acids exceed those of lipid peroxidation products (Baker et al., 2007), we predict that the reactive products of nitrative stress represent a group of highly potent endogenous TRPA1 activators, such that their production during inflammation may significantly enhance nociceptors activation.

**Materials and Methods**

All experiments were approved by the Johns Hopkins Animal Care and Use Committee or conducted according to the requirements of the United Kingdom Animals (Scientific Procedures) Act (1986) and strictly conformed to the ethical standards of GlaxoSmithKline Pharmaceuticals as appropriate.

**HEK293 Cell Culture.** Wild-type HEK293 cells, cells stably expressing human TRPV1 (hTRPV1-HEK), or cells stably expressing human TRPV1 (hTRPV1-HEK) were used in this study, as described previously (Taylor-Clark et al., 2008b). Cells were maintained in an incubator (37°C, 5% CO2) in Dulbecco’s modified Eagle’s medium (containing 110 μg/liter pyruvate) supplemented with 10% FBS and incubated (40 min, 37°C, 5% CO2). Neuron-covered coverslips were loaded with Fura 2 acetyoxymethyl ester (Fura-2AM; 8 μg/ml) for hTRPA1 and in L-15 media containing 20% FBS and incubated (40 min, 37°C). For imaging, the coverslip was placed in a custom-built chamber (bath volume of 600 μl) and superfused at 4 ml/min with Locke solution (34°C): 136 mM NaCl, 5.6 mM KCl, 1.2 mM MgCl2, 2.2 mM CaCl2, 1.2 mM NaH2PO4, 14.3 mM NaHCO3, and 10 mM dextrose (gassed with 95% O2–5% CO2, pH 7.3–7.4) for 15 min before and throughout each experiment by an infusion pump.

**Calcium Imaging.** HEK293-covered coverslips were loaded with Fura 2 acetoxyethyl ester (Fura-2AM; 8 μM; Invitrogen, Carlsbad, CA) in Dulbecco’s modified Eagle’s medium (containing 110 mg/liter pyruvate) supplemented with 10% FBS and incubated (40 min, 37°C, 5% CO2). Neuron-covered coverslips were loaded with Fura-2 AM (8 μM) in L-15 media containing 20% FBS and incubated (40 min, 37°C). For imaging, the coverslip was placed in a custom-built chamber (bath volume of 600 μl) and superfused at 4 ml/min with Locke solution (34°C): 136 mM NaCl, 5.6 mM KCl, 1.2 mM MgCl2, 2.2 mM CaCl2, 1.2 mM NaH2PO4, 14.3 mM NaHCO3, and 10 mM dextrose (gassed with 95% O2–5% CO2, pH 7.3–7.4) for 15 min before and throughout each experiment by an infusion pump.

**Changes in Intracellular Free Calcium Concentration (intracellular [Ca2+]free) were measured by digital microscopy (Carl Zeiss, Inc., Thornwood, NY) equipped with in-house equipment for ratiometric recording of single cells.** The field of cells was monitored by sequential dual excitation, at 352 and 380 nm, and the analysis of the image ratios used methods described previously to calculate changes in intracellular [Ca2+]free (Taylor-Clark et al., 2008b). The ratio images were acquired every 6 s. Superfused buffer was stopped 30 s before each drug application, when 300 μl of buffer was removed from the bath and replaced by 300 μl of 2× test agent solution added between image acquisitions. After treatments, neurons were exposed to KCl (30 s, 75 mM) to confirm voltage sensitivity. At the end of experiments, both neurons and HEK cells were exposed to ionomycin (30 s, 1 μM) to obtain a maximal response.

**For the analysis of Fura-2 AM-loaded cells, the measurement software converted ratiometric information to intracellular ([Ca2+]free) using Tsien parameters (([Ca] = Kd ((R - Rmin)(Rmax - R)) (b)) particular to this instrumentation and the HEK cells and dissociated mouse vagal neurons. Preliminary calibration studies yielded an Rmin (352 nm/380 nm ratio under calcium-free conditions) of 0.3 for both HEK cells and mouse sensory neurons and an Rmax (320/380 ratio under calcium-saturating conditions) of 18 and 14 for HEK cells and neurons, respectively. E (380 in calcium-free conditions/380 in calcium-saturating conditions) was estimated as being 10, and the Kd was estimated as being 224 nM. In the following experimental studies, we did not specifically calibrate the relationship between ratiometric data and absolute calcium concentration for each specific cell, choosing instead to use the parameters provided from the calibration studies and relate all measurements to the peak ionomycin response in each viable cell. This effectively provided the needed cell-to-cell calibration for enumerating individual cellular responses. Only cells that had a response to ionomycin were included in analyses. At each time point for each cell, data were presented as the percentage change in intracellular ([Ca2+]free) normalized to ionomycin: response = 100 × ([Ca2+]free - [Ca2+]het)/([Ca2+]max - [Ca2+]het), where [Ca2+]het was the apparent [Ca2+]free of the cell at a given time point, [Ca2+]het was the cell’s mean baseline apparent [Ca2+]free measured over 120 s, and [Ca2+]max was the cell’s peak apparent [Ca2+]free during ionomycin treatment. For the neuronal experiments, neurons were defined as “responders” to a given compound if the mean response was greater than the mean baseline plus 2× the standard deviation. Only neurons that responded to KCl were included in analyses. Given that vagal and trigeminal ganglia are likely to be composed of heterogeneous neuronal populations, it is important to emphasize the point that results are presented in two distinct ways. First, the number of neurons responding (based on the criteria described above) to a given stimulus compared with the total...
number of neurons is reported. Second, the mean percentage change in intracellular [Ca\(^{2+}\)]\(_{\text{free}}\) normalized to ionomycin of those neurons that (based on the above criteria) were defined as responders is reported.

**Whole-Cell Voltage Clamp.** Conventional whole-cell patch-clamp recordings were performed at room temperature (21–24°C) using a Multiclamp 700B amplifier and pCLAMP 9 software (Molecular Devices, Sunnyvale, CA). Pipettes (3–4 MΩ) fabricated from borosilicate glass (Sutter Instruments, Novato, CA) were filled with an internal solution composed of 140 mM CsCl, 4 mM MgCl\(_2\), 10 mM HEPES, and 5 mM EGTA; pH was adjusted to 7.2 with CsOH. Coverslips were superfused continuously during recording with an external solution composed of 140 mM NaCl, 2 mM MgCl\(_2\), 5 mM CaCl\(_2\), 10 mM HEPES, and 10 mM t-glucose (pH adjusted to 7.4 with NaOH) and gassed with 95% O\(_2\)/5% CO\(_2\). Only cells with membrane potential was held at

**Chemicals.** Stock solutions (200× +) of all agonists were dissolved in 100% ethanol (final concentration of 0.5% ethanol or less). 9-OA-NO\(_2\) and oleic acid were purchased from Cayman Chemicals (Ann Arbor, MI). Fura 2AM was purchased from Molecular Probes (Carlsbad, CA). AF-18 was purchased from BIOMOL Research Laboratories (Plymouth Meeting, PA). HC030031 was purchased from Tocris Bioscience (Ellisville, MO). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). Because of the reported instability of 9-OA-NO\(_2\) in aqueous solutions [half-life\(_{\text{aq}}\) of approximately 2 h (Goreczynski et al., 2007)], 9-OA-NO\(_2\) was dissolved into the appropriate buffer within 5 min of experimental use.

**Results**

9-OA-NO\(_2\) Activates TRPA1 Expressed on HEK293 Cells. We have shown previously that HEK293 cells stably transfected with human TRPA1 (hTRPA1-HEK) responded, in calcium imaging assays, to the reactive electrophilic products of oxidative stress, such as 4HNE and 8-iso prostaglandin A\(_2\) (Taylor-Clark et al., 2008a,b). Using the same hTRPA1-HEK cells, we found that 9-OA-NO\(_2\) (30 nM–30 μM; for structure, see Fig. 1A) activated TRPA1 channels (maximal response of 47 ± 1.5% of ionomycin, \(n = 156\)) with an approximate EC\(_{50}\) of 1 μM (Fig. 1B). The potency of 9-OA-NO\(_2\) at TRPA1 channels is 10-fold greater than the canonical selective TRPA1 agonist AITC, which activated the hTRPA1-HEK cells (maximal response of 50 ± 1.3% of ionomycin, \(n = 269\)) with an approximate EC\(_{50}\) of 10 μM (Fig. 1C). 9-OA-NO\(_2\) (100 nM–100 μM) failed to activate nHEK cells (maximal response of 3.2 ± 0.13% of ionomycin, \(n = 369\); Fig. 1B), suggesting that the increase in cytosolic calcium in the HEK cells caused by 9-OA-NO\(_2\) required TRPA1 channels. We investigated the effect of oleic acid on TRPA1 channels. Oleic acid (100 nM–100 μM) failed to activate hTRPA1-HEK cells (maximal response of 0.73 ± 0.12% of ionomycin, \(n = 168\); Fig. 1C), suggesting that the addition of the NO\(_2\) group onto the fatty acid was crucial to TRPA1 channel activation.

We have previously demonstrated that the highly reactive electrophile 4-oxonononal (4ONE), which activates hTRPA1-HEK cells with an approximate EC\(_{50}\) of 2 μM, is also an agonist for TRPV1 channel, although at 100 μM (Taylor-Clark et al., 2008a). We investigated whether or not 9-OA-NO\(_2\) was also capable of activating TRPV1 channels. Using calcium imaging of hTRPV1-HEK cells, we found that 9-OA-NO\(_2\) (100 nM-100 μM) failed to activate TRPV1 channels (\(n = 168\), Fig. 1C). As expected, the hTRPV1-HEK cells responded robustly to the canonical TRPV1 agonist capsaicin (300 nM, maximal response of 34 ± 1.1% of ionomycin, \(n = 168\), data not shown).

We next investigated the mechanism by which 9-OA-NO\(_2\) activates TRPA1 channels. It has been reported that nitrated fatty acids may mediate some of their biological actions via the release of nitric oxide (NO) (Schofer et al., 2005). It is conceivable that NO then directly nitrosylates the channel causing activation, as has been shown for other TRP channels (Yoshida et al., 2006). Indeed, NO donors have been shown to have a weak agonist effect on TRPA1 channels (Sawada et al., 2008; Takahashi et al., 2008). We confirmed the weak agonist effect on TRPA1 activity of two different NO donors, sodium nitroprusside (300 μM) and SIN-1 (300 μM), which caused an increase in calcium in hTRPA1-HEK cells (\(n = 75\)) of 8.7 ± 0.56% and 5.0 ± 0.31% of ionomycin,
respectively (data not shown). We then investigated the contribution of NO to 9-OA-NO₂-induced TRPA1 activation using the NO scavenger carboxy-PTIO. Incubating hTRPA1-HEK cells with 1 mM carboxy-PTIO for 10 min had no effect on the activation of TRPA1 by 9-OA-NO₂ (3 μM): maximal response of 49 ± 2.3% of ionomycin (n = 80) and 46 ± 1.7% of ionomycin (n = 212) for vehicle and carboxy-PTIO treatments, respectively (Fig. 2A). Overall the data suggests that NO is unlikely to play a major role in the activation of TRPA1 channels by 9-OA-NO₂.

Given that 9-OA-NO₂ activates TRPA1 channels in an NO-independent manner and that oleic acid has no effect on the channel, it is likely that the electrophilic C=C-NO₂ moiety is responsible for the TRPA1 channel activation. This would be consistent with previous reports that direct covalent modification of TRPA1 channel cysteines induces activation (Hinman et al., 2006; Macpherson et al., 2007a). 9-OA-NO₂ is a reactive electrophilic molecule that has been shown to readily adduct amino acid residues such as cysteines (Michael reaction) (Baker et al., 2007). Indeed, when the TRPA1 activation potency of 9-OA-NO₂ is compared with other endogenous TRPA1 “covalently modifying” agonists investigated in our heterologous system (Fig. 2B, and see Taylor-Clark et al., 2008a,b), the rank order of -LogEC₅₀ [9-OA-NO₂ (6) > 4ONE (5.8) > 4HNE (5) > 8-iso PGA₂ (4.5)] is almost identical to the rank order of second-order rate constants for the reaction of glutathione’s cysteine residue in model systems [9-OA-NO₂ (183 M⁻¹·s⁻¹) > 4ONE (145 M⁻¹·s⁻¹) > 4HNE (13 M⁻¹·s⁻¹) > 8-iso PGA₂ (0.7 M⁻¹·s⁻¹)] (Baker et al., 2007). This suggests that modification of cysteines may play a role in the activation of TRPA1 by 9-OA-NO₂. For human TRPA1 channels, covalent modification (Michael reaction)-induced TRPA1 activation is dependent on the presence of three crucial cysteine residues (Cys619, Cys639, and Cys663) and one lysine residue (Lys708) on the channel’s intracellular N terminus (Hinman et al., 2006). We hypothesized that 9-OA-NO₂ would fail to activate TRPA1 channels with mutations at these four residues. Using plasmid cDNA encoding the mutant hTRPA1-3C/K-Q and wild-type hTRPA1 channels (see Materials and Methods), we found that, as expected, 9-OA-NO₂ (3 μM) activated wild-type hTRPA1 channels (maximal response of 50 ± 2.1% of ionomycin, n = 166) but failed to activate the mutant channel (maximal response of 3.0 ± 1.0% of ionomycin, n = 18), whereas menthol (300 μM), which activates TRPA1 channels independently of Cys619, Cys639, and Cys663 (Xiao et al., 2008), did activate the mutant (maximal response of 33 ± 7.0% of ionomycin; Fig. 2C). Neither 9-OA-NO₂ nor menthol activated ntHEK cells [maximal responses of 0.45 ± 0.12% and 1.7 ± 0.16% of ionomycin (n = 88), respectively]. The data clearly suggest that 9-OA-NO₂ activates TRPA1 via covalent modification.

It is noteworthy that, unlike products of oxidative stress such as 4ONE and 4HNE, 9-OA-NO₂ has been shown to form Michael adducts with cysteine residues in a manner that can be reversed by the thiol-containing reducing agents dithiothreitol (DTT) and GSH (Batthyany et al., 2006). Thiol-reducing agents are present in vivo in both extracellular and intracellular compartments, and their levels are sensitive to the redox state of the environment (Szabó et al., 2007; Valko et al., 2007). DTT (1–5 mM) has previously been shown to reverse the activation of TRPA1 channels by H₂O₂ but not by 15-deoxy-Δ¹²,14-prostaglandin J₂ or 4HNE (Andersson et al., 2007; Takahashi et al., 2008). In calcium imaging assays of hTRPA1-HEK cells, we found that 7-min treatment with 10 mM DTT failed to reverse the activation of TRPA1 by 9-OA-NO₂ (3 μM): maximal response of 51 ± 1.1% (n = 204) and 49 ± 1.2% (n = 259) of ionomycin for vehicle and DTT treatments, respectively (Fig. 2D). We found a similar lack of reversibility when using 250 μM GSH ethyl ester (membrane-permeant form of GSH) (data not shown).

9-OA-NO₂ Activates TRPA1-Expressing Nociceptive Sensory Neurons. We and others have previously identified TRPA1 channel responses in subpopulations of native somatosensory and visceral sensory neurons from trigeminal,
vagal and dorsal root ganglia (Bandell et al., 2004; Jordt et al., 2004; Nassenstein et al., 2008). These TRPA1-expressing neurons almost always also respond to capsaicin, the TRPV1 agonist. Here we used calcium imaging to address the hypothesis that 9-OA-NO2 would activate sensory neurons that also respond to AITC, the canonical TRPA1 channel agonist, and to capsaicin. 9-OA-NO2 (10 μM) activated approximately 60% of trigeminal dissociated sensory neurons and 40% of vagal dissociated neurons (Fig. 3A). AITC (100 μM) and capsaicin (1 μM) activated similar proportions of the dissociated neurons, although there seemed to be a greater percentage of capsaicin-sensitive neurons in the vagal ganglia compared with the trigeminal ganglia. When only those neurons that responded to 9-OA-NO2 were combined, the mean responses demonstrated that 9-OA-NO2 (10 μM) caused a robust activation of sensory neurons (maximal response of 35 ± 3.4% and 36 ± 3.3% of ionomycin for vagal and trigeminal neurons, respectively) that also responded strongly to AITC and capsaicin (Fig. 3, B and C), suggesting that the actions of 9-OA-NO2 actions were restricted to nociceptive neurons, respectively) that also responded strongly to AITC and capsaicin. 9-OA-NO2 (10 μM) activating 20 of 101 neurons with a maximal response of 5.3 ± 0.9% of ionomycin (Fig. 4A). As expected, TRPA1(−/−)TRPV1(−/−) mice were indistinguishable from TRPA1(−/−) mice with 9-OA-NO2 (10 μM) activating 20 of 101 neurons with a maximal response of 5.3 ± 0.9% of ionomycin (Fig. 4A). As expected, TRPA1(−/−)TRPV1(−/−) mice also failed to respond to both AITC and capsaicin.

We further investigated the responses of native neurons to 9-OA-NO2 in whole-cell voltage clamp of vagal neurons. In the nominal absence of Ca2+, 9-OA-NO2 (10 μM) induced an

**TRPA1(−/−) Neurons Are Insensitive to 9-OA-NO2.** To confirm the molecular identity of the 9-OA-NO2-activated channels in native nociceptors, we compared responses of wild-type vagal neurons with those of vagal neurons derived from TRPA1(−/−) mice. In calcium imaging assays, 80 of 195 wild-type vagal neurons responded to 9-OA-NO2 (10 μM) with a maximal response of 35 ± 3.4% of ionomycin. However, only 34 of 124 TRPA1(−/−) neurons responded to 9-OA-NO2 with a dramatically reduced maximal response of 6.8 ± 0.6% of ionomycin, indicating that TRPA1 channels were responsible for the great majority of the 9-OA-NO2 response (Fig. 4A). As expected, the TRPA1(−/−) neurons also failed to respond to AITC (100 μM) but responded robustly to capsaicin (1 μM). Although 9-OA-NO2 had no observable effect on our hTRPV1-HEK cells, it was possible that the minor residual 9-OA-NO2-induced response in TRPA1(−/−) neurons was due to electrophile-dependent TRPV1 activation (Salazar et al., 2008; Taylor-Clark et al., 2008a). We addressed this hypothesis using mice with genetic deletion of both TRPA1 and TRPV1 channels. Consistent with our hTRPV1-HEK cell data, the neuronal responses of TRPA1(−/−)/TRPV1(−/−) mice were indistinguishable from TRPA1(−/−) mice, with 9-OA-NO2 (10 μM) activating 20 of 101 neurons with a maximal response of 5.3 ± 0.9% of ionomycin (Fig. 4A). As expected, TRPA1(−/−)/TRPV1(−/−) neurons also failed to respond to both AITC and capsaicin.

We further investigated the responses of native neurons to 9-OA-NO2 in whole-cell voltage clamp of vagal neurons. In the nominal absence of Ca2+, 9-OA-NO2 (10 μM) induced an

![Fig. 2. 9-OA-NO2 activates TRPA1 via covalent modification. A, mean ± S.E.M. Ca2+ responses of hTRPA1-HEK cells to 9-OA-NO2 (3 μM, 60 s), with (gray line, n = 212) and without (black line, n = 80) pretreatment with NO scavenger carboxy-PTIO (1 mM). B, Dose-response relationships of Ca2+ responses of hTRPA1-HEK cells for 9-OA-NO2, 4HNE, 4ONE, and 8-iso PGA2 (data comprise >156 cells; some data taken from Taylor-Clark et al., 2008a,b). Data represent the maximal response during the 60-s agonist treatment taken from mean cell response versus time curves (note that the S.E.M. is contained within symbol). C, mean ± S.E.M. Ca2+ responses to 9-OA-NO2 (3 μM, 60 s) and menthol (300 μM, 180 s) of nHEK cells (broken line, n = 88), HEK cells transiently transfected with hTRPA1 (black line, n = 166) and HEK cells transiently transfected with hTRPA1–3C/K-Q (gray line, n = 18). D, effect of DTT (10 mM, gray line, n = 259) and vehicle (black line, n = 204) on the mean ± S.E.M. Ca2+ responses of hTRPA1-HEK cells to 9-OA-NO2 (3 μM, 60 s).
inward current in 7 of 10 wild-type neurons (mean current density $12.5 \pm 8.3$ pA/pF), which was reversed by HC30031 (20 μM) (Fig. 4, B and D), the selective TRPA1 antagonist with an IC$_{50}$ of approximately 1 μM (McNamara et al., 2007). However, 9-OA-NO$_2$ (10 μM) had virtually no effect on TRPA1(−/−) neurons, with only 1 of 9 responding (current density 0.19 pA/pF) (Fig. 4, C and D). As expected, capsaicin (1 μM) responses were no different in neurons from wild-type and those from TRPA1(−/−) mice: four of eight responded with mean current density of 170 ± 52 pA/pF and seven of nine responded with mean current density of 158 ± 59 pA/pF, respectively. Taking the calcium imaging and voltage clamp data together, we conclude that the activation of native neurons by 9-OA-NO$_2$ is overwhelmingly dependent on TRPA1 channels.

9-OA-NO$_2$ Induces Action Potential Discharge from Visceral C Fibers via TRPA1. The effect of 9-OA-NO$_2$ on nociceptive nerve endings was analyzed using extracellular recording techniques in an ex vivo vagal innervated mouse lung preparation (Kollarik et al., 2003). Nociceptive vagal C fibers were considered those nerve fibers that responded with action potential discharge to capsaicin and α,β-methylene ATP. We have previously shown that TRPA1 agonists activate only this bronchopulmonary nerve population (Nassenstein et al., 2008; Taylor-Clark et al., 2008b). In seven experiments, the C fiber under study (conduction velocities ranged from 0.4 to 0.7 m/s) responded strongly with action potential discharge to capsaicin (0.3 μM) and α,β-methylene ATP (10 μM). In seven of seven of these capsaicin sensitive nerve fibers, 9-OA-NO$_2$ (30 μM) evoked action potential discharge (Fig. 5, A and 5). The action potential discharge in response to a 1-ml infusion of 9-OA-NO$_2$ delivered over 20 s had an onset within the 20-s delivery period, and generally persisted for only approximately 2 to 3 min. The total number of action potentials averaged 227 ± 51 (Fig. 5A). The peak frequency of discharge induced by 9-OA-NO$_2$ averaged 12 ± 2Hz, which was approximately 50% of that observed with capsaicin (24 ± 4Hz, added at the end of the experiment). The response to 9-OA-NO$_2$ was reproducible within a given nerve fiber. Treating the tissue a second time 20 min after the cessation of action potential discharge resulted in a response not significantly different from the first response (Fig. 5A). AP-18 (30 μM), the selective TRPA1 antagonist with an IC$_{50}$ of approximately 3 μM (Petrus et al., 2007) nearly abolished the 9-OA-NO$_2$-induced action potential discharge in the lung C fibers in five of five fibers tested (Fig. 5, A and B). We have
noted previously that there is a subpopulation of α,β methylene ATP-sensitive fibers in the mouse lung that are insensitive to capsaicin (Kollarik et al., 2003). We evaluated two of these capsaicin-insensitive fibers, and both were found also to be insensitive to 9-OA-NO₂.

Discussion

Our findings demonstrate that the nitrated fatty acid 9-OA-NO₂ is a stimulator of somatosensory and visceral nociceptors via the selective and direct activation of TRPA1.

Fig. 4. 9-OA-NO₂ fails to activate TRPA1(−/−) vagal neurons. A, mean ± S.E.M. Ca²⁺ responses of vagal neurons responding to 9-OA-NO₂ (10 μM). Response to AITC (100 μM) and capsaicin (Caps, 1 μM) also shown. Data comprise neurons from wild-type mice (black squares, 80 of 196 neurons responding), neurons from TRPA1(−/−) mice (gray squares, 34 of 124), and neurons from TRPA1(−/−)/TRPV1(−/−) mice (white squares, 20 of 101). Blocked line denotes the 30-s application of agonist. All neurons responded to KCl (75 mM) applied immediately before ionomycin. B, representative trace of the inward current evoked in a wild-type vagal neuron (held at −60 mV) by 9-OA-NO₂ (10 μM) and capsicain (1 μM). C, representative trace of the inward current evoked in a TRPA1(−/−) vagal neuron (held at −60 mV) by 9-OA-NO₂ (10 μM) and capsicain (1 μM). D, mean ± S.E.M. Inward current density (pA/pF) of vagal neurons responding to 9-OA-NO₂ (10 μM). Data comprise neurons from wild-type mice (black column) and neurons from TRPA1(−/−) mice (white column).

Fig. 5. 9-OA-NO₂ activation of C-fiber terminals. A, mean ± S.E.M. Total action potential discharge from individual identified bronchopulmonary C fibers to 9-OA-NO₂ (30 μM) in paired experiments: control and vehicle-treated fibers (n = 5) and control and 30 μM AP-18-treated fibers (n = 5). All C fibers responded to capsicain (300 nM) at the end of the experiment. Only one fiber was assessed in each preparation. B, representative trace of action potential discharge from a single bronchopulmonary C fiber evoked by 9-OA-NO₂ (30 μM) in the absence and presence of AP-18 (30 μM), followed by the response to capsicain (300 nM). Inset, action potential wave form of the individual bronchopulmonary C fiber.
channels. Based on our concentration-response analysis in both neurons and hTRPA1-HEK cells, we can conclude that this compound is the most potent endogenous TRPA1 agonist thus far described.

9-OA-NO₂ activated hTRPA1 channels in a heterologous system at concentrations just above those found in plasma samples from healthy humans (Baker et al., 2005) and well within the range of concentrations that OA-NO₂ induces other (non-neuronal) biological effects (Freeman et al., 2008; Trostchansky and Rubbo, 2008). The parent compound of 9-OA-NO₂, oleic acid, had no effect on hTRPA1, suggesting that the addition of the highly electrophilic nitro group was responsible for the actions of 9-OA-NO₂ on TRPA1, rather than the hydrocarbon chain or the carboxylic acid group. Nitrated fatty acids have been shown to be stable in lipophilic environments, but they have been shown to be reversibly by reports that NO donors, including sodium nitroprusside, are thought to be mediated by the NO-derived RNS (Radi, 2004; Ricciardolo et al., 2006; Szabó et al., 2004), which have been shown to contribute in vivo to many of NO’s pathophysiological and cytotoxic effects (Salvemini et al., 2006) and to multiple disease states including asthma, chronic obstructive pulmonary disease, viral-induced pneumonia, cystic fibrosis, ischemic-reperfusion injury, circulatory shock, arthritis, colitis, and pain (Radi, 2004; Ricciardolo et al., 2006; Szabó et al., 2004; Nassenstein et al., 2008). In our experiments, we found that 9-OA-NO₂ activated a population of small-diameter neurons as well as nociceptive sensory nerves in trigeminal, vagal, and dorsal root ganglia (Bandell et al., 2004; Jordt et al., 2004; Nassenstein et al., 2008). In our experiments, we found that 9-OA-NO₂ activated a population of small-diameter neurons as well as nociceptive sensory nerves in trigeminal, vagal, and dorsal root ganglia (Bandell et al., 2004; Jordt et al., 2004; Nassenstein et al., 2008). In our experiments, we found that 9-OA-NO₂ activated a population of small-diameter neurons that also responded to AITC, another TRPA1 agonist, and capsaicin, the TRPV1 agonist. Similar results were seen for both trigeminal and vagal neurons, suggesting that somatosensory and visceral nociceptors are activated by the nitrated fatty acid. Using TRPA1(−/−) vagal neurons, we confirmed in calcium imaging and voltage-clamp studies the molecular identity of the target of 9-OA-NO₂ in sensory neurons as being TRPA1, which is consistent with TRPA1 being the sole target of acrolein and 4HNE (products of lipid peroxidation) (Bautista et al., 2006; Macpherson et al., 2007b; Trevisani et al., 2007). Previous studies had shown that the lipid peroxidation product with the greatest electrophilicity, 4ONE (Doorn and Petersen, 2002; Baker et al., 2007), was able not only to activate TRPA1 channels but also to gate TRPV1 channels (Taylor-Clark et al., 2008a). Given that 9-OA-NO₂ is more electrophilic than 4ONE, as determined by cysteine addition (Baker et al., 2007), we would have predicted that 9-OA-NO₂ would have activated hTRPV1-HEK cells. In addition, another oleic acid derivative, N-oleoylthanolamine, has been shown to gate TRPV1 channels (Movahed et al., 2005). However, 9-OA-NO₂ failed to activate TRPV1 channels, and there was no difference between the response to 9-OA-NO₂ in vagal neurons from TRPA1(−/−) mice and TRPA1(−/−) TRPV1(−/−) mice. This lack of effect suggests that TRPV1 activation by reactive molecules is not solely dependent on the degree of electrophilicity.

The importance of the actions of 9-OA-NO₂ on TRPA1 channels was confirmed at the level of the sensory nerve terminals in ex vivo extracellular bronchopulmonary C-fiber recordings. We have previously shown that mouse vagal afferent capsaicin-sensitive C fibers innervating the lungs can be activated by TRPA1 agonists and that these responses are abolished by TRPA1 antagonists and by genetic deletion of TRPA1 channels (Nassenstein et al., 2008; Taylor-Clark et al., 2008a). As predicted from the in vitro studies, 9-OA-NO₂ induced robust action potential discharge from bronchopulmonary capsaicin-sensitive C-fiber terminals in a manner that was inhibited by the selective TRPA1 antagonist AP-18. This result is consistent with previous reports that lipid peroxidation products and AITC and other isothiocyanates evoke pain, local reflexes and central reflexes through the activation of TRPA1 channels on nociceptive sensory nerves (Trevisani et al., 2007; Andersson et al., 2008; Taylor-Clark et al., 2008a;b; Bessac et al., 2009). Many of NO’s pathophysiological and cytotoxic effects are thought to be mediated by the NO-derived RNS (Radi, 2004), which have been shown to contribute in vivo to inflammatory models (Salvemini et al., 2006) and to multiple disease states including asthma, chronic obstructive pulmonary disease, viral-induced pneumonia, cystic fibrosis, ischemic-reperfusion injury, circulatory shock, arthritis, colitis, and pain (Radi, 2004; Ricciardolo et al., 2006; Szabó et al.,
In 2007, there are inorganic stimulants that could contribute to the formation of RNS, for example nitrogen oxides (NO\textsubscript{x}) in polluted air and cigarette smoke. The contribution of nitrosative stress has diminished (Jain et al., 2008). Finally, it is likely that nitrosative stress can contribute to nociception in inflammation.

Acknowledgments

We thank Dr. Donald MacGlashan, Jr., and Sonya Meeker for technical assistance, and Dr. M. Allen McAlexander for insightful discussion regarding this manuscript.

References


Energies 2007. In addition, much of the detected nitrosative stress has diminished (Jain et al., 2008). Finally, it is likely that nitrosative stress can contribute to nociception in inflammation.


**Address correspondence to:** Bradley J. Undem, 5501 Hopkins Bayview Circle, Baltimore MD 21224. E-mail: bundem@jhmi.edu